Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/8/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Renier Brentjens?

Renier J. Brentjens

Director of Cellular Therapeutics

MSKCC

HQ Phone:  (212) 639-2000

Email: b***@***.org

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

MSKCC

1275 York Avenue

New York City, New York,10065

United States

Company Description

Memorial Sloan Kettering Cancer Center is the world's oldest and largest private cancer center, having devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, it is one of 45 National Cancer In...more

Background Information

Employment History

Consulting Editor

Journal of Clinical Investigation


Affiliations

Juno Therapeutics, Inc.

Co-Founder


Sloan-Kettering Cancer Center

Leukemia Specialist


Terrapinn Limited

ADVISORY BOARD Member


The Chemotherapy Foundation

Member of Laboratory


Sadelain

Member of Laboratory


Education

MD

SUNY Buffalo


Web References(110 Total References)


IO360° Keynote, Dr Carl June Featured in NYT's Article on Setting the Body's "Serial Killers" Loose on Cancer | The Conference Forum

theconferenceforum.org [cached]

The New York Times also highlighted IO360° speakers Dr Arie Belldegrun, President and CEO, Kite Pharma and Dr Renier Brentjens, director of cellular therapeutics at Memorial Sloan Kettering Cancer Center.


Advisory board | Antibody

www.terrapinn.com [cached]

Renier Brentjens
Renier Brentjens Director, Cellular Therapeutics Memorial Sloane Kettering Cancer Center


Juno Therapeutics |

junotherapeutics.com [cached]

DR. RENIER BRENTJENS
DR. RENIER BRENTJENS Scientific co-founder Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale-New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service. As a medical oncology fellow at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells" currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens' lab has expanded this CAR technology to target additional tumor antigens. More Info on Dr. Brentjens Michel Sadelain and Renier J. Brentjens of Memorial Sloan Kettering Cancer Center, for winning the esteemed New York Intellectual Property Law Association (NYIPLA) "Inventor of the Year" award. Sadelain and Brentjens were recognized for their extensive work in the design of chimeric antigen receptors (CARs).


www.mskcc.org

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
(From left) Investigators Isabelle Rivière, Michel Sadelain, and Renier Brentjens are founders of Juno Therapeutics. Dr. Sadelain and two other Memorial Sloan Kettering researchers - Renier Brentjens, Director of Cellular Therapeutics, and Isabelle Rivière, Director of the Cell Therapy and Cell Engineering Facility - are playing a critical role in the formation of Juno and are founding scientists of the company. (All three researchers will continue in their roles at Memorial Sloan Kettering.) Pictured: Renier J. Brentjens Renier J. Brentjens - Researcher Profile


ASGCT News

www.asgt.org [cached]

Renier J. Brentjiens, MD, PhD
Memorial Sloan Kettering Cancer Center


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory